Chen Schor

Salesforce Mimecast Outlook Microsoft Office 365 Greenhouse.io Amazon AWS Oracle Cloud Google Font API Vimeo Mobile Friendly New Relic Google Tag Manager Apache Remote AI

biotechnology research gamma delta t cells cell therapy allogeneic t cells car t cell therapy autoimmune diseases cancer treatments t cell activation immune reset b cell depletion clinical trials phase 1 trials off-the-shelf therapies drug development clinical data biotechnology drug marketing applications hematologic malignancies solid tumors immunotherapy tissue-homing immune surveillance proprietary manufacturing process therapeutic efficacy clinical biomarker data b-cell non-hodgkin lymphoma lupus nephritis systemic lupus erythematosus systemic sclerosis vaccine development fda fast track designation investigational new drug cellular therapies biopharmaceuticals late-stage development preclinical development therapeutic modalities immune effector cells natural killer cells cytokine release syndrome tumor microenvironment gene-engineered cell therapies drug discovery drug exposure health & wellness clinical translation regulatory strategy clinical-stage biotechnology cell therapies allogeneic gamma delta t cells cancer treatment innovative therapies investigational therapies patient-centered approach oncology hematology patient advocacy strategic partnerships therapeutic candidates healthcare professionals regulatory environments reimbursement landscapes market research competitive analysis transformative treatments patient outcomes gamma delta car t cell therapies idiopathic inflammatory myopathy clear cell renal cell carcinoma cancer-specific targets t cell receptor-like monoclonal antibodies health care health wellness & fitness hospital & health care